Conagen Expands Portfolio Beyond Gamma-Decalactone to 20 new non-GMO Lactones

Conagen, a Boston-based biotechnology company focusing on research and development, announced today its breakthrough development in the commercial production of natural aromatic compound, γ-Decalactone from natural substrates using its proprietary technology.

Conagen, a Boston-based biotechnology company focusing on research and development, announced today its breakthrough development in the commercial production of natural aromatic compound, γ-Decalactone from natural substrates using its proprietary technology. Found in many ripe fruits and particularly peaches, γ-Decalactone is a versatile compound used commercially in formulations with distinctive fruit flavors of peach, apricot and strawberry in food, beverage, fragrance, nutrition, renewable materials, and pharmaceutical markets.

The technology created for the γ-Decalactone product provides for more than 20 different lactones, many of which have not been available commercially because of a lack of reliable sources. This positions the company as a leader in the world of ingredient development. "The strengthening and expansion of Conagen's lactone production platform will better meet consumers' demand for nature-based, clean ingredients," said Oliver Yu, Ph.D., co-founder, and CEO of Conagen.

The compound is a member of a much larger family of lactones. Variations in the structures of lactones define their unique sensory properties with mainly fruity and buttery characteristics. These diverse characteristics create a wider spectrum of application options for manufacturers that use lactone flavors in their products.

"Conagen's lactone products are natural and non-GMO, making them ideal for use in a variety of consumer products," said Vice President of Research and Development, Casey Lippmeier, Ph.D.

For the last 10 years, Conagen has successfully developed one of the largest portfolios of ingredient products for its customers. 

Tags : #conagenexpandsportfoliogammadecalactone

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Transforming Brain Healthcare: India's Visionary Task Force for Neurological DisordersApril 25, 2024
The Battle Against Malaria: Rising Trends and Vaccine InnovationsApril 25, 2024
Talc and Asbestos Controversy: Inside Johnson & Johnson's Courtroom StruggleApril 25, 2024
The Hidden Struggles of Parenthood: Addressing Isolation, Loneliness, and BurnoutApril 25, 2024
FDA Confirms Bird Flu Virus Remnants in Pasteurized Milk: Safety and Regulatory InsightsApril 24, 2024
Sarvodaya Hospital Redefines Total Knee Replacement Surgery with Augmented Reality April 23, 2024
Fateh Education announces partnership to expand educational opportunities for Indian studentsApril 23, 2024
10 Strategies to counter disinformation for the healthcare digital ecosystemApril 23, 2024
Is Selling Over-the-Counter (OTC) Drugs in General Stores A Step Towards Affordable Healthcare in IndiaApril 23, 2024
Student Health Crisis: Food Poisoning Incident Strikes Pune Coaching CentreApril 23, 2024
The Impact of Diabetes on Kidney Health: Diabetic Nephropathy ExplainedApril 23, 2024
Toddler Hospitalized After Consuming Expired Chocolates: Health Concerns RaisedApril 23, 2024
After months of diagnostic delay, a migrant worker could access TB services only when a community health worker met himApril 22, 2024
Indian Spices Contaminated with Cancer-Causing Chemical: Hong Kong Food Regulators Issue WarningApril 22, 2024
FTCCI organised a Workshop on Rooftop Kitchen GardeningApril 20, 2024
Children in Cities Exposed to Elevated Lead Levels: Study Reveals Urgent Health ConcernApril 20, 2024
Biocon Ventures into Weight-Loss Drug Market with Semaglutide DevelopmentApril 20, 2024
Innovative AI Assistance Empowers Moscow Doctors to Detect Cervical Spine Issues through MRI ScansApril 20, 2024
Air India Express ties up with AISATS for AeroWash Automated Aircraft Exterior Cleanings April 19, 2024
IndoSup raises strategic funding led by CCI group promoters Naresh Sharma and Satish Sharma; investors include Yatra.com’s Rohan Mittal April 19, 2024